No abstract

A second generation of tissue sensitizers has been formulated for the photodynamic ablation of cancer. The photophysical and biologic properties of these agents will determine their activity and clinical use. Investigations of sensitizer properties are discussed, providing a foundation for sensitizer selection, followed by a summary of clinical reports. Tissue sensitizers may be particularly effective for the noninvasive ablation of early cancers.

Photodynamic Therapy (PDT) of obstructing esophageal tumors relieves dysphagia and improves quality of life. Low laser light doses are effective, with a high correlation between the tissue dose and the depth of tumor necrosis. Compared to NdYAG laser therapy, PDT is better tolerated and results in greater palliation of longer duration. Few complications are associated with either therapy.